| |
Active, Not Recruiting
|
HALT PKD Progression of PKD (HALT PKD)
|
Intervention:
|
Drugs - lisonopril, telmisartan |
|
Sponsor:
|
University of Pittsburgh Medical Center |
Study Phase:
|
III |
| Status: |
Active; enrollment complete |
| Age: |
15-64 |
|
Enrollment goal:
|
1,018 |
|
Description:
|
To assess the effectiveness of anti-hypertensive drugs telmisartan and lisinopril on PKD progression and its cardiovascular complications in two different levels of kidney function, GFR more than 60 mL/min/1/73m^2 and GFR between 25-60 mL/min/1.73m^2. |
| Additional Info: |
The Data Collection Center is now located at the University of Pittsburgh Medical Center. |
| Website: |
NIH Study Details |
|
|
Tolvaptan Tempo 3 / 4 Trial
|
Intervention:
|
Drug - Tolvaptan |
|
Sponsors:
|
Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Co., Ltd. |
|
Study Phase:
|
III |
| Status: |
Active; enrollment complete |
| Age Group: |
18-50 |
|
Enrollment goal:
|
1,500 |
|
Description:
|
To evaluate the long-term effectiveness and safety of Tolvaptan by monitoring total kidney volume and cyst volumes by magnetic resonance imaging and measuring a composite of clinical markers in ADPKD patients. |
| Websites: |
NIH Study Details
|
|
|
Sirolimus (Rapamune) for ADPKD
|
Intervention:
|
Drug - Rapamycin |
|
Sponsor:
|
The University of Zurich |
|
Study Phase:
|
III |
| Status: |
Active, enrollment complete |
| Age Group: |
18-40 |
|
Enrollment goal:
|
100 |
|
Description:
|
To investigate whether a low dose of sirolimus retards cyst growth and slows renal functional deterioration in patients with ADPKD. |
| Contact: |
Andreas Serra, MD 41 44 255 33 84 or andreas.serra@usz.ch |
| Website: |
NIH Study Details |
|
|
Pilot Study of Rapamycin as Treatment for ADPKD
|
Intervention:
|
Drug - Rapamycin |
|
Sponsor:
|
The Cleveland Clinic |
|
Study Phase:
|
I & II |
| Status: |
Active, not recruiting |
| Age Group: |
18-75 |
|
Enrollment goal:
|
30 |
|
Description:
|
To compare the effects of an anti-proliferative, anti-angiogenesis and tumor-progression-blocking agent on disease progression in ADPKD. Due to the intensive and frequent testing schedule, enrollment is limited to local patients only. |
| Contact: |
Susan Wirth 216-444-0124 or wirths@ccf.org |
| Website: |
NIH Study Details |
|
|
Somatostatin in Polycystic Kidney: A Long-term Three Year Follow-up Study
|
Intervention:
|
Drug - Long-acting somatostatin |
|
Sponsor:
|
Mario Negri Institute for Pharmacological Research |
|
Study Phase:
|
III |
| Status: |
Active, not recruiting |
| Age Group: |
18-75 |
|
Enrollment goal:
|
78 |
|
Description:
|
To compare the effects on disease progression of a three year treatment regimen using long-acting somatostatin or placebo in patients with ADPKD and normal renal function or mild to moderate renal insufficiency. |
| Contact: |
Norberto Perico, MD 0039 035-45351 or perico@marionegri.it |
| Website: |
NIH Study Details |
|
|
Octreotide in Severe Polycystic Liver Disease
|
Intervention:
|
Drug - Octreotide (long-acting somatostatin) |
|
Sponsor:
|
Mayo Clinic; Novartis |
|
Study Phase:
|
II & III |
| Status: |
Active, not recruiting |
| Age Group: |
18-80 |
|
Enrollment goal:
|
42 |
|
Description:
|
To evaluate the effect of Octreotide LAR on liver volumes of patients with severe polycystic liver disease who are not candidates for or decline surgical treatments such as liver cyst fenestration or liver transplantation. |
| Contact: |
Marie Hogan, M.D., Ph.D. 507-538-9851
Linda Page 507-538-9851 |
| Website: |
NIH Study Details |
|
|
Open Label Extension of LOCKCYST Trial
|
Intervention:
|
Drug - Lanreotide |
|
Sponsor:
|
Radboud University/IPsen |
| Study Phase: |
II & III |
| Status: |
Unknown |
| Age Group: |
18-88 |
|
Enrollment goal:
|
54 |
|
Description:
|
Continuation of LOCKCYST Trial. |
| Website: |
NIH Study Details
|
|
|
High Water Intake to Slow Progression of PKD
|
Intervention:
|
Water |
|
Sponsor:
|
New York University School of Medicine |
| Study Phase: |
II |
| Status: |
Active, not recruiting |
| Age Group: |
18-65 |
|
Enrollment goal:
|
20 |
|
Description:
|
To evaluate the changes in urine composition in PKD patients versus healthy individuals with high water intake by monitoring urinary biomarkers. |
| Contact: |
Irina Barash, MD 212-263-5851 or irina.barash@nyumc.org |
| Website: |
NIH Study Details
|
|
|
Somatostatin in Patients with ADPKD and Moderate to Severe Renal Insufficiency (ALADIN 2)
|
Intervention:
|
Octreotide-LAR |
|
Sponsor:
|
Mario Negri Institute for Pharmacological Research |
| Study Phase: |
III |
| Status: |
Active, not recruiting |
| Age Group: |
18-75 |
|
Enrollment goal:
|
80 |
|
Description:
|
To assess the efficacy of one year treatment with long-acting somatostatin analogue (Octreotide LAR)
compared to placebo in slowing kidney and liver growth rate in patients with ADPKD and moderate/severe
renal insufficiency. |
| Contact: |
Norberto Perico, Mario Negri Institute for Pharmacological Research |
| Website: |
NIH Study Details
|
|
|
|